Drug Trial Radar · NCT03824912
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Last checked: Nov 20, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
831
Actual
Start
Aug 23, 2018
Primary completion
Jan 24, 2019
Study completion Jan 24, 2019
Sponsor
- Lead sponsor
- Encube Ethicals Pvt. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Novum Pharmaceutical Research Services; ACM Global Laboratories
- First posted
- Jan 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Conditions
- Tinea Pedis
Interventions
Ketoconazole Cream 2%Drug
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Ketoconazole Cream 2% (G&W Laboratories Inc.)Drug
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
PlaceboDrug
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population)Time frame: Two weeks after the end of treatment (Day 56 ± 4) (Equivalence)
- Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Superiority: Modified Intent-to-Treat Population)Time frame: Two weeks after the end of treatment (Day 56 ± 4) (Superiority)
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Long Beach Clinical Trial Services, Inc.
Long Beach, California
International Dermatology Research, Inc.
Miami, Florida
FXM Research Corp.
Miami, Florida
San Marcus Research Clinic, Inc.
Miami Lakes, Florida
FXM Research Miramar
Miramar, Florida
MOORE Clinical Research, Inc.
Tampa, Florida
PEAK Research, LLC
Upper Saint Clair, Pennsylvania
FXM Research International
Belize City, Belize
FXM Research International
Castries, Saint Lucia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.